Fresenius SE & Co. KGaA Share Price

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 16:35:41 19/04/2024 BST 5-day change 1st Jan Change
26.9 EUR +0.94% Intraday chart for Fresenius SE & Co. KGaA +5.82% -4.17%

Financials

Sales 2024 * 23.02B 24.52B 1,983B Sales 2025 * 24.04B 25.61B 2,071B Capitalization 15.15B 16.14B 1,305B
Net income 2024 * 1.42B 1.51B 122B Net income 2025 * 1.77B 1.89B 153B EV / Sales 2024 * 1.33 x
Net Debt 2024 * 15.48B 16.49B 1,333B Net Debt 2025 * 14.81B 15.77B 1,276B EV / Sales 2025 * 1.25 x
P/E ratio 2024 *
10.4 x
P/E ratio 2025 *
8.5 x
Employees 193,865
Yield 2024 *
3.46%
Yield 2025 *
3.94%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Fresenius SE & Co. KGaA

1 day+0.94%
1 week+5.82%
Current month+7.60%
1 month+6.32%
3 months+2.36%
6 months+8.03%
Current year-4.17%
More quotes
1 week
25.29
Extreme 25.29
26.94
1 month
24.32
Extreme 24.32
26.94
Current year
24.32
Extreme 24.32
29.20
1 year
23.93
Extreme 23.93
31.22
3 years
19.69
Extreme 19.69
47.60
5 years
19.69
Extreme 19.69
52.32
10 years
19.69
Extreme 19.69
80.07
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 11/04/21
Director of Finance/CFO 44 31/12/18
Compliance Officer - 17/07/23
Members of the board TitleAgeSince
Director/Board Member 69 19/05/15
Chairman 69 31/12/19
Director/Board Member 63 12/05/16
More insiders
Date Price Change Volume
19/04/24 26.9 +0.94% 1,374,985
18/04/24 26.65 +0.53% 896,088
17/04/24 26.51 -0.38% 1,219,818
16/04/24 26.61 +4.56% 1,964,221
15/04/24 25.45 +0.12% 696,423

Delayed Quote Xetra, April 19, 2024 at 04:35 pm

More quotes
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
26.9 EUR
Average target price
36.22 EUR
Spread / Average Target
+34.64%
Consensus